China has granted the first invention patent to a Covid-19 vaccine co-developed by biopharmaceutical firm CanSino Biologics Inc in the country, which experts said demonstrates the vaccine-s originality and creativity. According to a Global Times report, the vaccine is a recombinant adenovirus vaccine named Ad5-nCoV co-developed by CanSino with a team led by Chinese military infectious disease expert Chen Wei.

"The grant of the patent further confirmed the vaccine-s efficacy and safety, and convincingly demonstrated the ownership of its intellectual property rights IPR," CanSino said in a statement on Sunday. An officially granted patent would enhance the market-s confidence in Chinese-developed Covid-19 vaccines, "especially that of the international market".